IP Library Granted Patent US 10,493,131
Granted Patent B2
US 10,493,131 · App. 14/240,842 · Granted Dec 3, 2019

Materials and methods for modulating activity of bone marrow derived cells

Inventors: Kirk P. Conrad (Gainesville, FL); Mark S. Segal (Gainesville, FL)
Assignee: University of Florida Research Foundation, Incorporated
A61K38/2221C07K16/26C07K16/2869C12N15/1136C12N15/1138
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,493,131
App. No.
14/240,842
Granted
Dec 3, 2019
Kind
B2
Abstract

The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating conditions amenable to treatment by recruitment of bone marrow-derived cells, such as BMDEC and bone marrow-derived angio-osteogcnic progenitor cell.

Claims (15)

1. A method for stimulating bone marrow-derived endothelial cell (BMDEC) mobilization and integration in a subject having been diagnosed with a disease or condition caused or made worse by insufficient vasculogenesis, wherein said method comprises administering, to the subject in need of such BMDEC mobilization and integration, an amount of relaxin effective to stimulate BMDEC mobilization and integration, and collecting the peripheral blood of the subject to evaluate BMDEC mobilization and integration, and wherein the disease or condition is selected from the group consisting of muscular dystrophy, neonatal respiratory distress syndrome, and organ transplantation.

2. The method of claim 1 , wherein the relaxin induces an increase in BMDEC activity and/or an increase in BMDEC nitric oxide production.

3. The method of claim 2 , wherein BMDEC activity includes BMDEC proliferation and/or migration.

4. The method of claim 1 , wherein the administration is selected from one of the following: local, systemic, oral, parenteral, intramuscular, and intravascular.

5. The method of claim 1 , wherein the relaxin is effective in preserving function and long-term patency of a dialysis access.

6. The method of claim 1 , wherein the relaxin is effective to increase blood flow, promote vasculogenesis and/or promote vessel regeneration.

7. The method of claim 1 , wherein the subject has had organ transplantation.

8. A method for stimulating bone marrow-derived endothelial cell (BMDEC) mobilization and integration in a subject having been diagnosed with muscular dystrophy, wherein said method comprises administering, to the subject in need of such BMDEC mobilization and integration, an amount of relaxin effective to stimulate BMDEC mobilization and integration.

9. The method of claim 8 , wherein the relaxin induces an increase in BMDEC activity and/or an increase in BMDEC nitric oxide production.

10. The method of claim 8 , wherein BMDEC activity includes BMDEC proliferation and/or migration.

11. The method of claim 8 , wherein the administration is selected from one of the following: local, systemic, oral, parenteral, intramuscular, and intravascular.

12. A method for stimulating bone marrow-derived endothelial cell (BMDEC) mobilization and integration in a subject having been diagnosed with neonatal respiratory distress syndrome, wherein said method comprises administering, to the subject in need of such BMDEC mobilization and integration, an amount of relaxin effective to stimulate BMDEC mobilization and integration.

13. The method of claim 12 , wherein the relaxin induces an increase in BMDEC activity and/or an increase in BMDEC nitric oxide production.

14. The method of claim 12 , wherein BMDEC activity includes BMDEC proliferation and/or migration.

15. The method of claim 12 , wherein the administration is selected from one of the following: local, systemic, oral, parenteral, intramuscular, and intravascular.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 9, 2016
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040579/0768 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2014
From: CONRAD, KIRK P.; SEGAL, MARK S.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 032874/0019 →
Continuity (2)
Provisional Application 61529662 · Aug 31, 2011
Related Publication 20140242074A1 · Aug 28, 2014